Founder & CEO, Bradley Burnam, to Ring NASDAQ “Closing Bell” at 4:00 PM ETWESTLAKE VILLAGE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces that its common stock is scheduled to commence trading today, October 8, 2025, on the Nasdaq Capital Market under ticker symbol “TTRX.” The Company’s registration statement on Form S-1 was declared effectiv ...

Core Viewpoint - Synovus Financial Corp. is set to discuss its pending merger with Pinnacle Financial Partners during a fireside chat at the BancAnalysts Association of Boston Conference on November 6, 2025 [1] Company Overview - Synovus Financial Corp. is a financial services company based in Columbus, Georgia, with approximately $61 billion in assets [3] - The company offers a range of services including commercial and consumer banking, wealth services, treasury management, mortgage services, premium finance, asset-based lending, structured lending, capital markets, and international banking [3] - Synovus operates branches in Georgia, Alabama, Florida, South Carolina, and Tennessee [3] - The company is recognized as a Great Place to Work-Certified Company [3]

Core Points - Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company focused on developing products for chronic wound management, infertility, and cosmeceuticals for health and beauty [1][6] - The company will present at the Skyline Signature Series™ on October 8, 2025, at 11:00 AM ET, allowing investors to engage in real-time Q&A [1][2][3] Event Details - Event Name: Skyline Signature Series™ [3] - Date: October 8, 2025 [3] - Time: 11:00 AM ET [3] - Registration Link: https://us02web.zoom.us/webinar/register/WN_wWWf2nr8QZmKgzx7IaKrXA/registration [3] About Skyline Corporate Communications Group - Skyline Corporate Communications Group, LLC provides investor relations services and ensures a high-quality audience for public companies through careful vetting [4][5] - The firm has experience in strategic messaging and investor communications for public corporations across various industries [5]

MIAMI, Oct. 03, 2025 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) announced that it will report results for the fourth fiscal quarter ended September 30, 2025 on Monday, November 24, 2025 after the close of the financial markets. The Company will also host a conference call at 9:00 a.m. (Eastern Time) on Tuesday, November 25, 2025 to discuss its financial results. All interested parties are welcome to participate. You can access the conference call by dialing toll- ...

Core Viewpoint - AB Science has announced a slight delay in the publication of its half-year financial report for 2025, which is now scheduled for October 10, 2025, to allow auditors to complete their work [1][2]. Company Overview - AB Science, founded in 2001, is a pharmaceutical company focused on the research, development, and commercialization of protein kinase inhibitors (PKIs), targeting diseases with high unmet medical needs [3]. - The company has developed a proprietary portfolio of molecules, with its lead compound, masitinib, registered for veterinary medicine and under development for human medicine in various fields including oncology and neurological diseases [4].

Group 1 - The presentation is part of CenterPoint's 2025 Investor Update, featuring key management members including the CEO and CFO [1] - Management will discuss projections and forward-looking statements based on current beliefs and available information [2] - Forward-looking statements are subject to risks and uncertainties, with actual results potentially differing materially [3] Group 2 - The call will include discussions on non-GAAP measures, specifically adjusted diluted earnings per share (EPS) [4]

Group 1 - The conference call is hosted by Larimar Therapeutics, with a slide deck available for participants [2] - The call includes forward-looking statements regarding the company's business expectations, plans for nomlabofusp development, and clinical trials [3] - The company emphasizes that the forward-looking statements are based on current beliefs and assumptions, which involve risks and uncertainties [4]

Core Points - NioCorp is hosting an event to discuss its operations and future prospects, featuring key executives including the Chairman, President, and CEO Mark Smith [1] - The event is conducted via Zoom, allowing participants to submit questions during the presentation [1] Group 1 - The presentation will include insights from the NioCorp team, focusing on the company's strategic direction and operational updates [3] - The event is structured to facilitate interaction, with a Q&A session planned after the presentation [1]

Core Insights - Nutriband Inc. will participate in the MicroCap Rodeo Conference on September 25, 2025, in New York City, where the company will discuss operational highlights, growth initiatives, and strategic direction for its AVERSA technology [1][4]. Company Overview - Nutriband Inc. is focused on developing a portfolio of transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch that utilizes AVERSA™ technology [4]. Conference Details - The MicroCap Rodeo Conference will feature approximately 15 microcap companies, providing investors with opportunities to discover unique stock ideas through presentations and one-on-one meetings [3]. - The conference will include industry guest speakers and networking opportunities, enhancing the engagement between investors and company executives [3]. Presentation Information - The company's presentation is scheduled for 10 AM on September 25, 2025, and will be available via live webcast, with management available for one-on-one meetings with approved investors [2].

Group 1 - The conference call is for the Spanish Broadcasting System's Second Quarter 2025 results [1] - Forward-looking statements regarding future results from current strategic initiatives will be discussed [2] - The company will not update or revise its forward-looking statements publicly [3] Group 2 - The company emphasizes the importance of adjusted OIBDA as a performance measure, excluding certain costs and expenses [4] - Adjusted OIBDA is considered useful for evaluating the performance of the company's stations [4] - The information provided is not a substitute for GAAP measures of operating performance or liquidity [5]